130 related articles for article (PubMed ID: 38582568)
21. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma.
Borojevic B; Chauhan A; Patterson S
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34244190
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
Tsutsumi Y; Kawamura T; Saitoh S; Yamada M; Obara S; Miura T; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
Leuk Lymphoma; 2004 Mar; 45(3):627-9. PubMed ID: 15160930
[TBL] [Abstract][Full Text] [Related]
23. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
Li X; Lin Q; Dong M; Wen JY; Wei L; Ma XK; Chen ZH; Wu XY
Leuk Lymphoma; 2010 Sep; 51(9):1678-85. PubMed ID: 20807095
[TBL] [Abstract][Full Text] [Related]
24. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Phipps C; Chen Y; Tan D
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):5-11. PubMed ID: 26705677
[TBL] [Abstract][Full Text] [Related]
25. Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive patients receiving chemotherapy for onco-hematologic malignancies.
Marignani M; Marzano A
J Clin Oncol; 2011 Mar; 29(8):e210; author reply e211. PubMed ID: 21220585
[No Abstract] [Full Text] [Related]
26. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
27. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma.
Uchiyama M; Tamai Y; Ikeda T
Int J Infect Dis; 2010 Mar; 14(3):e265-6. PubMed ID: 19665406
[No Abstract] [Full Text] [Related]
28. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.
Lam LK; Chan TSY; Hwang YY; Mak LY; Seto WK; Kwong YL; Yuen MF
Virol J; 2023 Aug; 20(1):168. PubMed ID: 37528444
[TBL] [Abstract][Full Text] [Related]
30. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab.
Pei SN; Liu YF; Kuo CY; Wang MC; Ma MC; Liao CK; Ng HY; Chen CH
Leuk Lymphoma; 2021 Dec; 62(12):2899-2906. PubMed ID: 34323157
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of hepatitis B virus (HBV)-DNA monitoring to detect HBV reactivation after systemic chemotherapy.
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
J Clin Oncol; 2011 Feb; 29(4):e100; author reply e101. PubMed ID: 21172888
[No Abstract] [Full Text] [Related]
32. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2019 Feb; 58(3):375-380. PubMed ID: 30210131
[TBL] [Abstract][Full Text] [Related]
34. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
35. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
Masarone M; De Renzo A; La Mura V; Sasso FC; Romano M; Signoriello G; Rosato V; Perna F; Pane F; Persico M
BMC Gastroenterol; 2014 Feb; 14():31. PubMed ID: 24533834
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
Coiffier B
Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
[TBL] [Abstract][Full Text] [Related]
37. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
[TBL] [Abstract][Full Text] [Related]
38. Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.
Montineri A; Nigro L; Chiarenza A; Larocca L; La Rosa R; Iacobello C; Di Raimondo F; Fatuzzo F
Leuk Lymphoma; 2010 Mar; 51(3):554-7. PubMed ID: 20141445
[No Abstract] [Full Text] [Related]
39. [Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B].
Chung SM; Sohn JH; Kim TY; Yoo KD; Ahn YW; Bae JH; Jeon YC; Choi JH
Korean J Gastroenterol; 2010 Apr; 55(4):266-9. PubMed ID: 20389182
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
